Although the association of MGMT with glioma prognosis is well-established [17, 45], our results indicate that USP7 may serve as both a GBM prognostic marker and a therapeutic target, potentially functioning in association with MGMT, as suggested by our TMA IF data. This evidence concerns the gene MGMT and central nervous system cancer.